Evidence map›Paper›PMID 41948601›Full record

ArticleInfection and drug resistance2026

Thrombomodulin as a Potentially Complementing Diagnostic Tool in Non-Pneumonic Bacterial Infections.

Katharina Friedrich, Aurelia Hübner, Noa Galtung, Britta Hecke, Kai Kappert, Wolfgang Bauer

Abstract read
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katharina FriedrichInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0009-0002-3566-9006
Aurelia HübnerDepartment of Emergency Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-3390-5581
Noa GaltungDepartment of Emergency Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-4379-9516
Britta HeckeInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Kai KappertInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0001-6976-0428
Wolfgang BauerDepartment of Emergency Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-1063-3237

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Soluble thrombomodulin (TM) has been proposed as an endothelial injury marker with potential diagnostic value, particularly for severe pneumococcal community-acquired pneumonia (CAP). Its validation could enable clinically meaningful patient stratification and support biomarker-guided therapy. This retrospective study evaluated the associations between serum TM levels and disease severity/origin in 80 patients with suspected acute infection. Methods: Serum TM concentrations were measured in patients presenting to the emergency department and adjudicated by an expert panel as pneumococcal CAP, non-pneumococcal CAP, other bacterial infections (non-pneumonic), viral pneumonia, or patients with clinically ruled-out infection (controls). Results: TM levels did not differ significantly between CAP patients and controls or those with other bacterial infections. However, highest TM concentrations were observed in patients with bacterial infections without pneumonia, significantly exceeding control levels. TM levels were not correlated with disease severity in CAP, determined by National Early Warning Score 2 (NEWS2), but were significantly elevated in non-pneumonic bacterial infections of moderate severity (NEWS2 5-6). Conclusion: In this cohort, TM was elevated in bacterial non-pneumonic infections but was not a specific marker for pneumococcal CAP. These findings indicate that TM predominantly reflects systemic endothelial injury, a hallmark of more severe bacterial infections, particularly those of non-pneumonic origin.

Indexed as

bacterial infectionscommunity-acquired pneumoniapneumococcal pneumoniaseverity of CAPthrombomodulin

Identifiers

PMID41948601
PMCPMC13050979

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.